Document:

c55318_ex10-2.htm

EX-10.2

 

CONSULTING
    AGREEMENT (the “Agreement”), dated as of October 20, 2008 between
    ELITE PHARMACEUTICALS, INC., a Delaware corporation having a
  principal place of business at 165 Ludlow Avenue, Northvale, New Jersey 07467 (the “Company”), and PARALLEX CLINICAL RESEARCH, a Consultant having an address at 218 Walker Place, West Hempstead, NY  11552 (“Consultant”).

INTRODUCTION

           The Company desires to engage Consultant to provide consulting services to Elite for Elite’s opioid abuse-resistant product, sustained release opioid product and other such products
that Elite may request assistance with (the “Products”), all as more fully described in Exhibit A hereto. To accomplish such purposes the Company and Consultant hereby agree as follows: 

ARTICLE I 

RETENTION: TERM: DUTIES

          1.1       Retention of Consultant;
Term.  The Company hereby retains the services of Consultant, and Consultant hereby agrees to render services to the Company, all in accordance with the terms and conditions
hereof, for a term (the “Term”) commencing on October 20, 2008 and terminating at such time as the Company shall notify Consultant in writing pursuant to Section 3.1 below.

          1.2     Duties. During
the Term, Consultant shall perform such consulting services for the Company, its subsidiaries and affiliates as may be required and assigned by the Company. These services shall include by way of illustration and not limitation include assistance in
development and execution of Elite’s regulatory and clinical program to assist in development of the Products and such other services as the Company shall request in writing from time to time. The parties acknowledge and agree that the services
shall be performed by Stuart Apfel (“Apfel”) on behalf of Consultant. Consultant has, and if necessary will engage its other employees with the proper skill, training and experience to provide the services; provided, that before any of
Consultant’s other employees provides services the Company shall agree to such Consultant employees. Consultant shall provide, and shall cause each such person to provide the services hereunder in a diligent and professional manner in
accordance with generally accepted industry standards.  The services of Consultant hereunder shall be performed at the applicable rates set forth in Section 2.1 hereof.  Consultant shall provide the Company with progress reports with respect to the
services rendered hereunder in reasonable detail on a periodic basis and as otherwise requested by the Company. Consultant shall be solely responsible for the payment of all salaries and other compensation to its employees, representatives or
agents. The Company shall have the right at all times to terminate the assignment of any employee of Consultant upon notice for any reason, in Company’s sole discretion.

 

          1.3     No
Conflict. Consultant represents and warrants to
the Company that it and its employees and representatives are
free to be engaged by the Company upon the terms contained in this Agreement and that there are no consulting agreements, employment contracts, restrictive covenants or other agreements or fiduciary obligations preventing or interfering with in any
manner whatsoever the full performance of Consultant’s duties hereunder.

          1.4     Relationship of Parties. The Company and Consultant acknowledge and agree that Consultant, its employees, representatives and agents are independent contractors and not employees of, or joint venturers or partners with, the Company. Consultant, its
employees, and representatives will not be entitled to any of the Company’s employee benefits
(including without limitation, pension, insurance, disability, overtime premium, vacation plans, and the like) and will not have any right to make commitments to third parties on behalf of the Company unless specifically authorized in writing by the
Company. Any employees or other representatives that Consultant may engage to provide services on behalf of the Company with the Company’s prior written consent shall remain the employees of Consultant and shall be paid directly by Consultant
for all services in this connection. Consultant shall be solely responsible for all obligations and reports covering Social Security, Unemployment Insurance, Workers’ Compensation, Income Tax and other reports and deductions required by any
applicable Federal, state or local law with respect to the services provided hereunder by Consultant, its employees and representatives. 

          1.5     Legal Compliance.
 Consultant, its employees and representatives will comply with all applicable governmental laws, ordinances, rules and regulations applicable to the performance of the services hereunder. 

          1.6     Appointment of Apfel.  During the Term, Apfel shall serve as the Company’s Chief Scientific Officer and Chief Medical Officer. 

ARTICLE II 

COMPENSATION

          2.1       Compensation.  For all services rendered by Consultant hereunder and all covenants and obligations undertaken by it pursuant to this Agreement, Consultant shall be compensated at the rate of $250 per hour
for the services of Stuart Apfel and $175 per hour for clinical research scientists, payable monthly and upon presentation of an invoice itemized by days worked; provided, however, that, in no event shall Consultant be entitled to compensation
(together with its employees’, representatives’ or agents’ billable hours) of more than $10,000.00 in any month, unless Consultant has obtained the prior written authorization of the Company. Consultant shall keep and shall cause
to be kept detailed monthly time sheets and is responsible for submitting such records to Company. All invoices hereunder shall be submitted by Consultant to the Company at the address set forth at the head of this Agreement. Consultant’s
federal identification number is 203418259. 

          2.2       Expenses.
Upon presentation of a written itemized account thereof with related receipts,
the Company shall from time to time pay to or reimburse Consultant for the 

2

reasonable and necessary travel expenses incurred by Consultant
in connection with the performance of its duties hereunder, which travel expenses
have been approved in writing in advance by the Company. 

ARTICLE III 

TERMINATION

          3.1     Term; Termination. The Company shall be entitled to terminate this Agreement immediately upon written notice to Consultant for any reason. Sections 1.3, 1.4, 1.5, Article 4 and Article 5 shall survive the termination or expiration of this
Agreement. Upon termination or expiration of this Agreement, the Company shall not have any further obligations to the Consultant hereunder. 

          3.2     Continued
Cooperation.  Consultant and/or
Apfel, as applicable, shall, during and after the expiration or termination of
this Agreement for any reason, at Company’s sole expense, provide such reasonable
cooperation as is requested by Company with respect to any internal or external
 agency or legal investigation (whether conducted by the Food and Drug Administration
(“FDA”), the Securities Exchange Commission (the “SEC”) or
otherwise), lawsuits, financial reports, or with respect to other matters within
its  knowledge, responsibilities or purview, upon reasonable notice. Consultant,
its employees and representatives, including Apfel, shall execute all lawful
documents reasonably necessary for Company to secure or maintain any Confidential
Information  (as defined below). 

          3.3     Return of Documents and Property. Upon the
expiration or termination of this Agreement, or upon the earlier request of the Company, Consultant, Apfel and Consultant’s legal or personal representatives will promptly return to the Company any and all information, documents or other
materials relating to or containing Confidential Information which are, and any and all other property of the Company which is, in Consultant’s and/or Apfel’s possession, care or control, regardless of whether such materials were created
or prepared by Consultant and/or Apfel, and regardless of the form of, or medium containing, such information, documents, including without limitation, all Company computers and hard drives, all computer files (whether or not such files are stored
on Consultant’s and/or Apfel’s personal computers), keys and any other physical property of Company. A breach of the foregoing obligations by any of Consultant’s employees and/or representatives, including without limitation, Apfel,
is deemed to be a breach by Consultant.

ARTICLE IV 

NON-DISCLOSURE, NON-COMPETITION AND NON-SOLICITATION

          4.1     Non-Disclosure.
Consultant acknowledges that, in performing its services hereunder, it will be exposed to certain confidential and proprietary information of the Company. Consultant, its employees and representatives shall not disclose or furnish to any other
person, firm or corporation, or utilize for it or their own benefit any Confidential Information.  For purposes of this Agreement “Confidential
Information is defined as (a) any information relating to 

3

any confidential process, technique or procedure used by the
Company, its subsidiaries and affiliates, including, but not limited to, any
patents and designs, projections, procedures, formulae, processes, techniques,
methodologies, business, financial or organizational or  administrative information,
personnel material and product, marketing or sales data; (b) the identity of
any products or compounds that are the subject of research, development, commercialization
or manufacture by the Company, including the progress  or status of any such
research or development efforts Company; or (c) any information of a confidential
nature obtained as a result of any prior, present or future relationship with
the Company, its subsidiaries or affiliates; (d) any trade secrets  of the Company,
its subsidiaries or affiliates; or (e) the name, address or other information
relating to any customer or supplier of the Company, its subsidiaries or affiliates.
It is further provided that the foregoing provisions shall not apply  to any
information that Consultant can document by clear and convincing evidence: 

	                     	
(a)    	
is now public knowledge or which hereafter becomes public knowledge through no fault of Consultant;
	
	 
	 	
(b)	
is properly provided to Consultant without violation of an obligation owed to the Company by an independent third party; or
	
	 
	 	
(c)	
was already in the Consultant’s possession at the time of receipt from the Company.
	
	 

Consultant will restrict access to Confidential Information to the minimum number of its employees and representatives as is necessary for the purpose of the performance of the services
hereunder and shall use best efforts to preserve and safeguard the Confidential Information.  Consultant shall advise its employees of the confidential nature of the Confidential Information and shall ensure that its employees and representatives
keep such information confidential and utilize such information only in accordance with the terms of this Agreement.

          4.2       Non-Solicitation;
Non-Competition. Consultant agrees that during the Term of this Agreement and for a period of one year thereafter, it will not, in any manner, directly or indirectly (a) be
employed by, engaged in or participate in the ownership, management, operation or control of, or act in any advisory, expert or other capacity for, any entity or consultant that competes with the Company, its subsidiaries or affiliates with the
Products being developed by the Company, its subsidiaries or affiliates and relating directly or indirectly to the Consultant’s work hereunder; (b) solicit or divert any business or any customer from the Company, its subsidiaries or affiliates
or assist any person, firm or corporation in doing so or attempting to do so; or (c) cause or seek to cause any person, firm or corporation to refrain from dealing or doing business with the Company, its subsidiaries or affiliates or assist any
person, firm or corporation in doing so; or (d) solicit or divert any employee from the Company, its subsidiaries or affiliates or assist any person, firm or corporation in doing so. 

4

          4.3       Securities
Laws. Consultant acknowledges that he is aware
(and that its employees have been advised) that the United States securities
laws (“Securities Laws”) prohibit Consultant, its employees
and any person or entity who has received material non-public information about
the Company from purchasing or selling securities of the Company or from  communicating
such information to any other person under circumstances in which it is reasonably
foreseeable that such person is likely to purchase or sell such securities in
reliance on such information. Consultant shall not do or perform any act  in
violation of any Securities Laws or other applicable securities law. 

          4.4       No Granting of
License. Nothing herein contained is intended or shall be interpreted as (i) granting or creating any right or license in or to Consultant with respect to any patent rights,
copyrights, trademarks, trade secretes, or other intellectual property or proprietary rights owned or controlled by the Company, or (ii) waiving or relinquishing any rights of enforcement that the Company may have with respect to patent, copyright,
trademark, trade secrets, or other intellectual or other proprietary infringement or misappropriation.

          4.5       Inventions. All data, results, ideas, discoveries, inventions, reports, or other works of authorship (including, without limitation, any derivative works) that are or may be patentable or subject to
copyright and that may be made, authored, discovered or otherwise conceived or invented by Consultant, including, without limitation, its employees, representatives, or agents, as a result of performing the services hereunder, whether alone or in
conjunction with others (collectively, the “Inventions”), and all right, title and interest in and to such Inventions throughout the world, shall be deemed a “work made for hire” (as such term is defined in Title 17 United States
Code Section 101) and shall the sole and exclusive property of the Company. To the extent any right, title or interest in or to such Inventions by operation of law or otherwise belong to Consultant, its employees, representatives, or agents, such
Inventions shall be deemed assigned upon discovery, conception or creation to the Company and shall become the sole and exclusive property of the Company, without any further act of Consultant, its employees, representatives, or agents. Consultant
agrees to treat, and shall cause its employees, representatives, or agents to treat, all such Inventions as Company’s Confidential Information hereunder. Consultant shall promptly communicate to Company, without publishing same, any Inventions
and all available information relating to any Inventions (with all necessary plans and models).

          Consultant
shall assist, and shall cause its employees, representatives, or agents to assist,
the Company in perfecting its ownership rights in Inventions and obtaining, maintaining
and defending any such Inventions. Consultant will, at the request of Company,
execute and perform, and cause its employees, representatives and/or agents,
as the case may be, to execute and perform, all such deeds, documents, acts and
things as Company and its duly authorized agents may deem necessary or desirable
to, among other things: (a) apply for, obtain and vest solely in the name of
Company, letters patent, copyrights, trademark registrations or other analogous
protection in any country throughout the world and when so obtained or vested
to renew, extend and restore the same; and (b) defend any opposition proceedings
in respect of such applications and any opposition proceedings or petitions or
applications for revocation or cancellation of such letters patent, copyright,
trademark registration or other analogous 

5

protection. In the event that Company is unable, after reasonable
effort, to secure Consultant’s signature on any application, assignment,
or other document or instrument relating to letters patent, copyright, trademark
or other analogous protection relating to a Invention, whether because of the
physical or mental incapacity of Consultant or for any other reason whatsoever,
 Consultant hereby irrevocably designates and appoints Company and each of its
duly authorized officers and agents as Consultant’s agent and attorney-in-fact,
to act for and in Consultant’s behalf and stead to execute and file any
such  applications and to do all other lawfully permitted acts to further the
prosecution and issuance of letters patent, copyright, trademark or other analogous
protection thereon with the same legal force and effect as if executed by Consultant.

          4.6       Indemnity Obligations of
Consultant. Consultant shall indemnify, defend and hold Company and its affiliates harmless from and against any and all claims, proceedings, losses, damages, liabilities, costs
and expenses (including reasonable attorneys’ fees) in connection with a breach of this Agreement by or for any of Consultant’s, its employees’, representatives’, or other agents’ acts and omissions hereunder. 

          4.7       Breach of
Provisions. If Consultant and/or any of its employees, agents or representatives breaches any of the provisions of this Article 4 in addition to and without limiting any other
remedies available to the Company at law or in equity, the Company shall be entitled to immediate equitable relief in the form of an injunction in any court to restrain any such breach or threatened breach and to enforce the provisions of this
Article 4 and such other relief as the court may determine to be necessary, reasonable or proper. Consultant acknowledges and agrees that there is no adequate remedy at law for any such breach or threatened breach and, in the event that any
proceeding is brought seeking injunctive relief, Consultant shall not use as a defense thereto that there is an adequate remedy at law. 

ARTICLE V 

MISCELLANEOUS

          5.1       Assignment. The rights and obligations of Consultant under this Agreement may not be assigned or delegated by Consultant without the prior written consent of the Company. 

          5.2       Binding Effect. This Agreement shall extend to and be binding upon Consultant, Apfel and their respective successors, permitted assigns, heirs and legal representatives, and shall inure to the benefit of the
Company, its successors and assigns. 

          5.3     Notices. Any notice required or permitted to be given under this Agreement to either party shall be sufficient if in writing and if sent by Federal Express or other similar express courier service, to
the address of such party set forth above, or to such other address as such party may hereafter designate by a notice given to the other party in the manner provided in this Section. 

          5.4       Waiver.
A waiver by a party hereto of a breach of any term, covenant or condition of
this Agreement by the other party hereto shall not operate or be construed as
a waiver 

6

of any other or subsequent breach by such
party of the same or any other term, covenant or condition hereof. 

          5.5       Entire Agreement. This Agreement sets forth the entire agreement between the parties with respect to the subject matter hereof and no waiver, modification, change or amendment of any of its provisions shall be
  valid unless in writing and signed by the party against whom such claimed waiver, modification, change or amendment is sought to be enforced. This Agreement supersedes all prior understandings, whether oral or written, between the Consultant and the
  Company.

          5.6       Authority. The parties each represent and warrant that they have the power, authority and right to enter into this Agreement and to carry out and perform the terms, covenants and conditions hereof.

          5.7       Applicable Law; Choice of
Forum. This Agreement shall be governed by and construed in accordance with the substantive laws of the State of New Jersey without giving effect to principles relating to
conflicts of law. Any legal action or proceeding filed in connection with this Agreement shall be filed in a forum in the State of New Jersey. The parties hereby consent to the sole and exclusive jurisdiction of the courts in the State of New Jersey
and agree not to raise any defense or make any argument that the pendency of any legal action or proceeding in such courts is inconvenient. 

          5.8       Severability. In the event that any of the provisions of this Agreement, or any portion thereof, shall be held to be invalid or unenforceable, the validity and enforceability of the remaining provisions
hereof shall not be affected or impaired but shall remain in full force and effect. 

* * * 

 

 

 

7

            IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the day and year first above written. 

	 	
    ELITE PHARMACEUTICALS, INC.	
	 	 	 	
	 	 	 	
	 	By:   	/s/
	    Chris Dick	 
	 	 	Chris Dick	
	 	 	Executive Vice President of Corporate	
	 	 	Development	
	 	 	 	
	 	 	 	
	 	 	 	
	 	
    PARALLAX CLINICAL RESEARCH	
	 	 	 	
	 	 	 	
	 	By:	/s/
	    Stuart Apfel	 
	 	 	Dr. Stuart C. Apfel, M.D.	
	 	 	President	

Agreed and Acknowledged that 

Stuart Apfel shall be bound by the

Terms of this Agreement as if he were

a party hereto in place of Parallax 

Clinical Research 

	 	 
	
Stuart Apfel	

 

 

8

SCHEDULE A

	
Assistance in development and execution of Elite’s regulatory and clinical program for its once-daily
opioid product.

	
Assistance in development and execution of Elite’s regulatory and clinical program for its
abuse-resistant opioid product.

 

 

 

 

 

9-- Converted by SEC Publisher, created by BCL Technologies Inc., for SEC Filing

Amendment No. 1 to 

Employment Agreement 

between ZYGO Corporation 

and J. Bruce Robinson 

ZYGO Corporation (the “Company”) and J. Bruce Robinson (“Executive”) are parties to an Employment Agreement dated January 15, 1999 (the “Agreement”). For good and valuable consideration, the Company
and Executive hereby amend the Agreement as follows:

Effective upon the closing of the merger pursuant to the Agreement and Plan of Merger dated October 15, 2008 among the Company, Electro Scientific Industries, Inc. (“ESI”) and certain other
parties (the “Closing”), a new Section 9(c) is added to the Agreement and Section 9(b) of the Agreement is amended, such sections to read in their entirety as follows: 

“(b)    Payments. Effective upon the Closing, all stock options to purchase shares of the Company’s stock held by Executive at the date of the Closing shall
automatically be deemed fully vested. If Executive’s employment is terminated by the Company or the acquiring or successor company for other than “justifiable cause” (as defined in Section 11(d) hereof) or Executive terminates his
Employment with the Company or the acquiring or successor company with “good reason” (as defined in Section 9(c) hereof) within one year after the Closing, the Company shall provide the following benefits to Executive (the “CIC
Benefits”): (a) continue existing health insurance, dental coverage, key man life insurance, AD&D and disability coverage in effect for Executive at the time of such employment termination for a period of the lesser of one year or until
covered by another plan, and (b) continue Executive’s salary for a one year period; provided, however that during the applicable period in which benefits are being paid by the Company, Executive agrees to maintain a consulting relationship with
the Company which shall not interfere with other obligations of Executive; provided, further, that the Company agrees to provide Executive at least six months prior notice of termination of Executive’s employment for other than
“justifiable cause” if such termination is to occur prior to the first anniversary of the Closing. If Executive resigns his Employment with the Company or the acquiring or successor company for any reason or his Employment is terminated by
the Company or the acquiring or successor company for other than “justifiable cause” (as defined in Section 11(d) hereof) within ninety (90) after the first anniversary date of the Closing, the Company shall provide the CIC Benefits to
Executive. Notwithstanding any other provision in this Agreement, the payment of the CIC Benefits shall be in lieu of any and all other payments that may be provided for in this Agreement (including without limitation payments that may be provided
for in Section 11(g)). Notwithstanding Section 2 of the Agreement, the provisions of this Section 9(b) shall remain in full force and effect during the period from the date of the Closing through the date that is 90 days after the first anniversary
date of the Closing unless Executive otherwise agrees in writing.

(c)    Good Reason. For the purposes of this Agreement, the term “good reason” shall mean any of the following events or conditions occurring with respect to
Executive at any time following the Closing: 

(i) a reduction in Executive’s base salary (other than in connection with a reduction in base salary of management employees generally) or any failure to pay Executive compensation or
benefits to which he is entitled within fifteen days of the date due; 

(ii) a relocation by the Company or the acquiring or successor company of Executive’s principal place of employment by more than fifty miles, other than a relocation that Executive has consented to;

(iii) a material diminution of the position, status or duties of Executive’s employment or of Executive’s working conditions (provided that there shall not be deemed to be a material diminution if Executive has a senior
management position with the Company, the acquiring company, the parent corporation of the acquiring company or a subsidiary of the parent corporation); or 

(iv) the failure by the Company or an acquiring or successor company to provide Executive with compensation and benefits, in the aggregate, substantially equivalent to those in effect immediately prior to the Closing.

Termination shall not be for “good reason” unless Executive has notified the Company in writing within 90 days of the initial occurrence of the event or condition that constitutes good reason and no remedy is effected
within 30 days and Executive terminates employment, if at all, within 90 days following the end of such 30 day period.”

Notwithstanding any provision to the contrary contained herein or in the Agreement, any payment otherwise required to be made to Executive on account of his separation from service (including, without limitation, payments and
benefits payable under subparagraph 1(b) above), to the extent such payment is properly treated as deferred compensation subject to Section 409A of the Internal Revenue Code of 1986 and the regulations and other applicable guidance issued by the
Internal Revenue Service thereunder, shall be delayed until the first business day after the expiration of six months from the date of the termination of Executive’s employment or, if earlier, the date of his death. On the delayed payment date,
there shall be paid to Executive (or his estate, as the case may be) in a single cash payment an amount equal to the aggregate amount of the payments delayed pursuant to the preceding sentence. 

ESI is a third party beneficiary of this Amendment by reason of the Agreement and Plan of Merger referred to in this Amendment. This Amendment may be amended or terminated only with the written consent of the Company, the
Executive and ESI.

	Dated: October 21, 2008 	 	 	 
	 	 	 	 
	 	 	 	 
	 	ZYGO Corporation	 
	 	 	 	 
	 	 	 	 
	 	By:	 /s/
        Walter A. Shephard	 
	 	Title:	  Chief
        Financial Officer	 
	 	 	 	 
	 	 	 	 
	 	 	 	 
	 	Executive:	 
	 	 	 	 
	 	 	 	 
	 	    /s/ J. Bruce Robinson	 
	 	J. Bruce Robinson

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00148-of-00352.parquet"}]]